Dr Karl Keegan to join Vectura Group

Will take responsibility for corporate development and investor relations

Vectura Group, a UK developer of inhaled therapies for the treatment of respiratory diseases, says Karl Keegan will join the firm as director of corporate development on 3 September. He will be primarily responsible for corporate development and investor relations.

Keegan has more than 20 years’ experience in the pharmaceutical industry, starting his career in research followed by a strategic planning role at SmithKline Beecham.

Prior to joining Vectura, he spent 12 years as a biotech analyst with a number of City firms including UBS and Bank of America, and more recently held cfo positions at Minster Pharmaceuticals and then Pharming Group.

After five years as director of investor relations & corporate communications, Julia Wilson has decided to leave the company to pursue personal interests.

You may also like

Drug Delivery

Vectura’s $62.7m inhalation centre granted planning permission

The state-of-the-art building is set to be completed in 2025 and will enable Vectura to expand its operations
Drug Delivery

Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Manufacturing

Vectura to provide development services for brain injury drug

The development work on Incannex Healthcare's inhaled drug product will be undertaken at Vectura’s Chippenham, UK facility
Ingredients

Accelerating excipient development for inhalable dosage forms with QbD

Whether they are simply giving an oral dose the bulk it needs to permit handling and swallowing or performing more complex functions that enable successful delivery and product performance, excipients are critical components of all drug formulations, explains Iain Davidson, Senior Manager, Pharmaceutical Development, Vectura
Manufacturing

Vectura expanding manufacturing capabilities in Chippenham

The company offers services to advance dry powder programmes from early development through clinical phases of development to small-scale commercialisation
Regulatory

Vectura earns $11m milestone with Hikma generic launch

The launch of the product follows approval by the US FDA
Finance

Vectura expands HPAPI capabilities in the UK

The facility at Chippenham is home to a combination of science laboratories and offices
Subscribe now